SciSparc Ltd. SPRC shares are trading higher Friday after the company announced it has launched a clinical trial of its combination of cannabidiol (CBD) and SciSparc's proprietary Palmitoylethanolamide, to treat the symptoms of autism spectrum disorder (ASD).
The Details:
SciSparc said that the trial will enroll 60 participants between the ages of 5-18 years old and will measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms.
Oz Adler, SciSparc's CEO stated, "Our pioneering treatment aims to reduce and alleviate the symptoms of autism along with reducing the side effects that are common when taking cannabis-based treatments, such as CBD."
On Wednesday, SciSparc announced the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel.
Shares of SPRC are up on heavy trading volume Friday. According to data from Benzinga Pro, more than 12.4 million shares have already been traded in the session, compared to the stock's 100-day average of 1.615 million shares.
Related News: What's Going On With Rivian Automotive Stock?
SPRC Price Action: According to Benzinga Pro, SciSparc shares are up by 53% at $11.35 at the time of publication.
Image: Bob G from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!